Globus Medical price target lowered to $67 from $75 at Canaccord

Canaccord analyst Kyle Rose lowered the firm’s price target on Globus Medical to $67 from $75 and keeps a Hold rating on the shares. The analyst said they reported solid Q4 results that showed encouraging momentum throughout the business, particularly in core US spine, trauma, and ex-Japan OUS spinal implants.